Clinical trial
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to…
NCT00423085 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00423085 |
|---|---|
| Title | Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease |
| Official title | A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Ono Pharmaceutical Co. Ltd Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Rivastigmine transdermal patch, Placebo |
| Enrollment | 859 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Jan 17, 2007 |
| Last update posted | Feb 10, 2014 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: